Mazdutide is a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Previous Phase 2 clinical trial results have demonstrated that mazdutide produces robust weight loss and offers benefits in improving various cardiometabolic risk factors.

The latest results from the GLORY-1 trial indicate that, among Chinese adults who are overweight or obese, treatment with mazdutide—compared to a placebo—leads to greater weight loss and a significant reduction in waist circumference. Furthermore, it contributes to cardiovascular health by notably lowering systolic blood pressure, triglycerides, total cholesterol, and uric acid levels.

For Chinese adults who are overweight or obese, mazdutide serves to both facilitate weight loss and mitigate cardiometabolic risks.

Mechanism of Action
1. GLP-1 receptor activation: Promotes insulin secretion, inhibits glucagon release, and reduces blood glucose fluctuations.
2. GCG receptor activation: Enhances lipolysis (fat breakdown) and energy metabolism, thereby reducing fat accumulation.
3. Central regulation: Acts on the appetite-regulating centers in the hypothalamus to increase satiety and decrease caloric intake.

Target Population
Patients with type 2 diabetes: Particularly those with poor glycemic control who are also obese.
Individuals with obesity: Specifically those with a BMI ≥30 kg/m², or those with a BMI ≥27 kg/m² accompanied by metabolic abnormalities.

.

•⁠  ⁠Credit/Debit Card  

•⁠  ⁠Apple Pay  

•⁠  ⁠Google Pay  

•⁠  ⁠Alibaba Pay (secure link)  

•⁠  ⁠Bank Transfer (SWIFT)   

•⁠  ⁠USDT (TRC20)  

•⁠  ⁠Bitcoin (BTC)

•⁠  ⁠Paypal